1-4 of 4
Ling Yuan Kong
Close
Sort by
Journal Articles

A Novel Small-Molecule Approach To Inhibit Jak2 Tyrosine Kinase Signaling.

Vaibhav Kapuria, MS, Geoffrey Bartholomeusz, PhD, Ling-Yuan Kong, PhD, William Bornmann, PhD, Zhenghong Peng, PhD, Ashutosh Pal, PhD, David Maxwell, PhD, Moshe Talpaz, MD, Nicholas Donato, PhD
Journal: Blood
Blood (2007) 110 (11): 1556.
https://doi.org/10.1182/blood.V110.11.1556.1556
Published: 2007
Journal Articles

Activation of a novel Bcr/Abl destruction pathway by WP1130 induces apoptosis of chronic myelogenous leukemia cells

Geoffrey A. Bartholomeusz, Moshe Talpaz, Vaibhav Kapuria, Ling Yuan Kong, Shimei Wang, Zeev Estrov, Waldemar Priebe, Ji Wu, Nicholas J. Donato
Journal: Blood
Blood (2007) 109 (8): 3470–3478.
https://doi.org/10.1182/blood-2006-02-005579
Published: 2007
Journal Articles

Antitumor Activity and Mechanism of Action of a Novel Stat3 Inhibitor, WP1066, Against Human B-Cell Non-Hodgkin’s Lymphoma and Multiple Myeloma.

Ling-Yuan Kong, MD, PhD, Vaibhav Kapuria, Geoffrey Bartholomeusz, PhD, Moshe Talpaz, MD, Waldemar Priebe, PhD, Nicholas J. Donato, PhD
Journal: Blood
Blood (2005) 106 (11): 1489.
https://doi.org/10.1182/blood.V106.11.1489.1489
Published: 2005
Journal Articles

Constitutive Activation of SRC-Family Kinases in Chronic Myelogenous Leukemia Patients Resistant to Imatinib Mesylate in the Absence of BCR-ABL Mutations: A Rationale for Use of SRC/ABL Dual Kinase Inhibitor-Based Therapy.

Nicholas J. Donato, PhD, Ji Wu, MD, Ling-Yuan Kong, MD, PhD, Feng Meng, MD, Francis Lee, PhD, Moshe Talpaz, MD
Journal: Blood
Blood (2005) 106 (11): 1087.
https://doi.org/10.1182/blood.V106.11.1087.1087
Published: 2005